To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

Neoplasms change over time through a process of cell-level evolution, driven by genetic and
epigenetic alterations. However, the ecology of the microenvironment of a neoplastic cell …

The ability to predict the future behavior of an individual cancer is crucial for precision
cancer medicine. The discovery of extensive intratumor heterogeneity and ongoing clonal …

Glioblastoma (GB) is the most common and aggressive primary brain malignancy, with poor
prognosis and a lack of effective therapeutic options. Accumulating evidence suggests that …

Patient-derived organoids (PDOs) have recently emerged as robust preclinical models;
however, their potential to predict clinical outcomes in patients has remained unclear. We report …

Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of
genomic data in the light of cancer evolution remains challenging. Here we demonstrate that …

MicroRNAs (miRNAs) show differential expression across breast cancer subtypes, and have
both oncogenic and tumour-suppressive roles 1 , 2 , 3 , 4 , 5 , 6 . Here we report the miRNA …

Cancer is a disease in which cells accumulate genetic aberrations that are believed to confer
a clonal advantage over cells in the surrounding tissue. However, the quantitative benefit …

What happens in early, still undetectable human malignancies is unknown because direct
observations are impractical. Here we present and validate a'Big Bang'model, whereby …

Genetic and epigenetic variation, together with transcriptional plasticity, contribute to
intratumour heterogeneity 1 . The interplay of these biological processes and their respective …